Choroidal neovascularisation (pathological myopia) - ranibizumab: evaluation report
01. Pre-meeting Briefing prepared by NICE
02. Final Scope
03. Final Matrix
04. Submission from the technology manufacturer – Novartis
05. NICE request to Manufacturer for clarification on their submission
06. Manufacturer clarification response
07. Consultee submission – Macular Society
08. Consultee submission – Royal National Institute of Blind People
09. Consultee submission – Royal College of Ophthalmologists
10. Consultee submission Royal College of Pathologists
11. Clinical expert perspective – Bailey
12. Patient expert personal perspective – Eaglen
13. Clinical expert perspective – Sivaprasad
14. Evidence Review Group Report prepared by Aberdeen HTA Group
15. Manufacturer factual accuracy check of Evidence Review Group report
16. Evidence Review Group – Erratum
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *
Choroidal neovascularisation (pathological myopia) - ranibizumab: evaluation report
25 October 2013 (9.92 Mb 19 sec) |
This page was last updated: 18 October 2013